Ionis Just Turned a Rare Disease Drug Into a $3 Billion Opportunity

Safety looked clean, too. Serious side effects actually occurred less often in patients on Tryngolza (9–11%) than on placebo (14%). The most common complaint was mild injection site reactions, which is par for the course with monthly shots.

First and Only

Tryngolza is now the first and only FDA-approved treatment specifically for severe hypertriglyceridemia that reduces both triglycerides and pancreatitis risk. That "first and only" designation matters enormously. It means no head-to-head competition on the label. Doctors treating sHTG patients have been stuck with a toolkit of statins, fibrates, and fish oil derivatives that often can't get the job done. Tryngolza offers something fundamentally different: an RNA-targeted therapy (a drug that intercepts the genetic instructions for a protein called apoC-III, which regulates triglyceride metabolism) delivered as a once-monthly shot.

Competitors are coming, though. Arrowhead Pharmaceuticals is running Phase 3 trials for plozasiran, another drug targeting apoC-III, with data expected later in 2026. The battle for this market is just getting started.

Wall Street Smells a Blockbuster

Before the expanded approval, analysts had pegged Tryngolza's peak sales potential at roughly $2 billion. In its Q1 2026 financial results, Ionis raised its own forecast to over $3 billion in peak annual net sales. William Blair followed suit, lifting its estimate to match.

The early commercial traction supports the optimism. Tryngolza generated about $105 million in U.S. net sales during 2025, all from the tiny FCS indication alone. First-quarter 2026 sales came in around $27 million, showing continued momentum even before the sHTG launch kicks in this month.

For context, $3 billion in peak sales would make Tryngolza one of the biggest cardiovascular/metabolic drugs in the industry. It would also be Ionis' first wholly owned multi-billion-dollar medicine, a milestone the company has been chasing for decades.

The Real Story: Ionis Is Becoming a Different Company

This approval isn't just about one drug. It's about Ionis rewriting its entire business model.

Historically, Ionis made money by licensing its RNA technology platform to partners. Royalties from Biogen's Spinraza (for spinal muscular atrophy) and collaborations with AstraZeneca kept the lights on. But in 2025, the company declared a "new chapter" as a commercial-stage biotech, planning four independent product launches over three years.

Tryngolza in FCS was launch number one. The sHTG expansion supercharges it. Donidalorsen for hereditary angioedema and zilganersen for Alexander disease are next in line. Combined with partner royalties, management expects to hit cash flow breakeven by 2028.

The financial trajectory is already shifting. Commercial revenue grew 49% in 2025 compared to the prior year, and the company guided for approximately 20% total revenue growth in 2026 (excluding a one-time $280 million licensing deal with Ono Pharmaceutical). Total 2026 revenue guidance sits at $875–900 million.

What Could Go Wrong

The biggest risk is execution. Having an FDA approval and actually converting 2.3 million potential patients into prescriptions are two very different things. Payer coverage negotiations will be critical; specialty biologics aren't cheap, and insurers will want to see real-world outcomes data before opening the gates wide.

Physician adoption is another question mark. Cardiologists and lipidologists have been managing sHTG with generic fibrates and omega-3s for years. Convincing them to prescribe a monthly injectable requires education, evidence, and a lot of sales reps knocking on doors. Ionis says it's expanding its sales force ahead of the July launch, but building commercial infrastructure from scratch is expensive and uncertain.

Then there's competition. Arrowhead's plozasiran targets the same protein and could offer quarterly dosing instead of monthly. If that data reads out well, the sHTG market could split quickly.

The Bottom Line

Ionis spent years as the brilliant inventor who let other companies sell its work. With Tryngolza's expanded approval, it finally has a product that could generate blockbuster revenue on its own terms. The clinical data is strong, the market is large, and the competition hasn't arrived yet.

The question isn't whether Tryngolza is a good drug. The FDA answered that twice. The question is whether Ionis can become a great commercial company. The next 18 months will tell us everything.